Abstract: The present invention relates to an Abelson murine leukaemia viral oncogene homolog 1 (ABL1) inhibitor for use in the treatment of ocular neovascularisation associated with a non-cancerous condition. The invention also relates to the use of an ABL1 inhibitor as a complementary therapy with VEGF or VEGF receptor inhibitor treatment and provides pharmaceutical compos itions and kits comprising one or both inhibitors.

Abstract: A method of construction. A first step involves stabilizing prefabricated load bearing walls for an underlying vertical level of a multi-story building. The walls have opposed surfaces and a top peripheral edge. A second step involves securing floor joists for an overlying vertical level to at least one of the opposed surfaces of the walls of one of the underlying vertical level. A third step involves installing prefabricated load bearing walls for the overlying vertical level along the top peripheral edge of the underlying vertical level. The walls have opposed surfaces and a top peripheral edge. The steps set forth above are repeated until a desired number of vertical levels are installed.